Another example is an anti-CL4 aptamer that inhibited triple-negative breast cancer (TNBC) cells and tumor growth by impacting the binding between epidermal growth factor receptor (EGFR) and integrin (Camorani et al., 2017). This evidence concerns the gene EGFR and triple-negative breast carcinoma.